Clinical Trials Using Nivolumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Nivolumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 401-412 of 412
< Previous 1 ... 15 16 17

  • Pepinemab with Nivolumab or Ipilimumab in Treating Patients with Stage III or IV Melanoma

    This randomized pilot phase I trial studies the side effects and best dose of pepinemab when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma. Pepinemab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as nivolumab, and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pepinemab with nivolumab or ipilimumab may work better in treating patients with stage III or IV melanoma.
    Location: 2 locations

  • Ipilimumab and Nivolumab as First-Line Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work as first-line therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Nivolumab and Cyclophosphamide in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    This phase I / II trial studies how well nivolumab and cyclophosphamide works in treating patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given nivolumab and cyclophosphamide may work better at treating acute myeloid leukemia and higher-risk myelodysplastic syndrome.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent, or Metastatic Endometrial Cancer

    This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial that has come back (recurrent) or spread to other places in the body (advanced or metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.
    Location: 29 locations

  • Nivolumab with and without Ipilimumab and Radiation Therapy in Treating Patients with Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma before Surgery

    This phase II trial studies how well nivolumab with and without ipilimumab and radiation therapy when given before surgery works in treating patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may work better in treating patients with undifferentiated pleomorphic sarcoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ipilimumab and Nivolumab in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work in treating patients with non-small cell lung cancer that is stage IIIB, stage IV, or that has come back. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Nivolumab and Ipilimumab in Treating Patients with Metastatic or Refractory Thyroid Cancer

    This randomized phase II trials studies how well nivolumab and ipilimumab work treating patients with thyroid cancer that has spread to other places in the body (metastatic) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Nivolumab and Cabozantinib in Treating Patients with Metastatic Triple-Negative Breast Cancer

    This phase II trial studies how well nivolumab and cabozantinib work in treating patients with triple negative breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib may work better in treating patients with triple negative breast cancer.
    Location: See Clinical Trials.gov

  • Short-term Fasting prior to Standard of Care PD-1 / PD-L1 Inhibitor Therapy for the Treatment of Advanced or Metastatic Skin Malignancy

    This phase I trial studies the side effects of short-term fasting in patients with skin malignancy that has spread to other places in the body (advanced or metastatic) treated with a PD-L1 or PD-1 inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab, cemiplimab, avelumab, atezolizumab, or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Undergoing short-term fasting prior to treatment with one of these PD-L1 or PD-1 inhibitors may potentially reduce the side effects of immunotherapy or even improve the effectiveness of immunotherapy in patients with skin malignancy.
    Location: 2 locations

  • Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

    This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
    Location: 1418 locations

  • Nivolumab in Preventing Lung Cancer in High Risk Current and Former Smokers with or without a History of Lung Cancer

    This phase II trial studies how well nivolumab works in preventing lung cancer in participants who are high risk current and former smokers with or without a history of lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • Intratumoral Microdosing of Motolimod in HNSCC

    This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via the CIVO device in patients with head and neck squamous cell carcinoma (HNSCC). CIVO stands for comparative in vivo oncology.
    Location: 2 locations


< Previous 1 ... 15 16 17